Key result
Ranolazine demonstrated dramatic antiarrhythmic effects, suppressing malignant ventricular tachycardia in a patient with nonischemic cardiomyopathy.
Case Report (n=1)
Ranolazine may have potent antiarrhythmic properties for suppressing malignant ventricular tachycardia in patients with nonischemic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for ranolazine in ventricular arrhythmias; controlled trials needed before clinical consideration in nonischemic cardiomyopathy.
Murdock et al. (2008) conducted a case report in Nonischemic cardiomyopathy with malignant ventricular tachycardia (n=1). Ranolazine was evaluated on Suppression of ventricular tachycardia. Ranolazine demonstrated dramatic antiarrhythmic effects, suppressing malignant ventricular tachycardia in a patient with nonischemic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: